Reports Q2 revenue $687M. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented, “AC Immune is entering the second half of 2024 with tremendous momentum. We are excited about the recently announced partnership with Takeda for ACI-24.060 as a potential best-in-class Abeta-targeted active immunotherapy. Enrollment in the ABATE Phase 2 trial of ACI-24.060 in AD continues to progress as planned.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACIU:
- AC Immune Reveals Pioneering Neurodegenerative Drug Technology
- AC Immune announces presentation of morADC at AAIC 2024
- AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
- AC Immune’s Alzheimer’s Drug Fast-Tracked by FDA
- AC Immune’s ACI-35.030 granted FDA Fast Track Designation